A61K36/734

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

Composition for preventing or treating hyperlipidemia

A method for preventing or treating hyperlipidemia includes administrating a composition consisting of a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract to a subject in need thereof. The composition may reduce an amounts of serum cholesterol and LDL-cholesterol and increase an amount of HDL-cholesterol, significantly reduce an amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduce an amounts of hepatic to cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS
20200016228 · 2020-01-16 ·

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects.

ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS
20200016228 · 2020-01-16 ·

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects.

ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS
20200016228 · 2020-01-16 ·

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects.

MICROBIAL CHINESE HERBAL MEDICINE FEED HAVING EFFECTS OF DETOXICATION,MUTTONY ODOR REMOVAL, FLAVOR ENHANCEMENT AND MUTTON QUALITY IMPROVEMENT
20240081375 · 2024-03-14 ·

A microbial Chinese herbal medicine feed having effects of detoxication, muttony odor removal, flavor enhancement and mutton quality improvement, comprising 190-1920 parts of feed substrate, 39-238 parts of additives, 1-65 parts of Chinese herbal medicine components, and 100-550 parts of forage powder; the Chinese herbal medicine components comprise fructus aurantii, dried tangerine peel, Amomum villosum and so on. The formula of the invention can obviously decrease the synthesis of short-chain fatty acids and C18 fatty acids in sheep, inhibit and block the further combination of C6, C8 and C10 into stable complexes or associations to the greatest extent and effectively improve the quality of the mutton, particularly effective in removing odor of the mutton.